Active Not RecruitingNCT03935685
Mirtazapine for depression and nausea during brain cancer treatment
About this title
Read the official source — NCT03935685Medication studyAges 18+United States
Understand this study
Who could participate?
Listed age limits: from 18 years.
- Listed locations
- OrangeSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: February 26, 2019
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 120
- Sponsor
- University of California, Irvine
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT03935685
- Official title
Show the full official title
Pilot Study of Mirtazapine for the Dual Treatment of Depression and Temozolomide-Induced Nausea and Vomiting (CINV) in Newly-Diagnosed High-Grade Glioma Patients on Temozolomide Therapy
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Orange
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of California, Irvine, a university.
Does this study involve medication?
Yes. The study involves medication, including Mirtazapine (Remeron).
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
